New drug combo aims to prevent breast cancer return in 1,800 patients
NCT ID NCT07441460
First seen Mar 20, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study tests whether a new drug combination (KN026 plus HB1801 and chemotherapy) works better than the standard treatment (trastuzumab, pertuzumab, and chemo) to prevent breast cancer from coming back after surgery. It includes 1,800 adults with HER2-positive breast cancer that has spread to lymph nodes. Participants will receive either the new or standard treatment and be followed for cancer recurrence or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201318, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.